Achromobacter xylosoxidans
Jump to navigation
Jump to search
| Achromobacter xylosoxidans | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Achromobacter xylosoxidans Achromobacter xylosoxidans
| ||||||||||||||
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Achromobacter xylosoxidans Yabuuchi and Yano 1981[1] | ||||||||||||||
| Type strain | ||||||||||||||
| ATCC 27061, BCRC 12839, CCM 2741, CCRC 12839, CCTM La 3521, CCUG 12689, CDC KC 1064, CDCKC1064, CECT 467, CECT 927, CGMCC 1.2007, CIP 71.32, DSM 10346, DSM 2402, DSMZ 10346, DSMZ 2402, EY 543, GIFL 543, GIFU 543, Hugh 2838, IAM 12684, IFO 15126, IMD 101001, JCM 9659, KACC 10205, KM 543, LMG 1863, NBRC 15126, NCIB 12033, NCIMB 12033, NCTC 1 O807, NCTC 10807, NRRL 84082, NRRL B-4082, NXRX 10807, PCM 2222, R-16924, R. Hugh 2838, R.Hugh 2838, RH 2838, RIMD 101001, strain KM 543, strain Takeda, VTT E-991282 Yabuuchi KM 543[2] |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]
Overview
Achromobacter xylosoxidans is a Gram-negative, aerobic, oxidase- and catalase-positive, motile bacterium with peritrichous flagella, from the genus Achromobacter found in water environments and was isolated from patients (pulmonary).[3][4] Achromobacter xylosoxidans can cause infections like bacteremia,[5][6] especially for patients who suffer from cystic fibrosis.[7] In 2013, the complete genome of an A. xylosoxidans isolate from CF patient was sequenced.[8]
Treatment
-
- Preferred regimen: most active agents are Piperacillin-Tazobactam, Meropenem AND Trimethoprim–Sulfamethoxazole whereas Ceftazidime is more active than Cefepime
- Alternative regimen: Colistin inhaled, could also be considered
- Note : Achromobacter (formerly Alcaligenes) xylosoxidans is a newly emerging microorganism isolated with increased frequency from the lungs of patients with cystic fibrosis. Combination therapy has been recommended for the treatment of Achromobacter xylosoxidans pulmonary exacerbations in cystic fibrosis
References
- ↑ LPSN bacterio
- ↑ Strain info of Achromobacter xylosoxidans
- ↑ Journal of Clinical Microbiology [1]
- ↑ UniProt
- ↑ PubMed
- ↑ Achromobacter xylosoxidans Bacteremia: Report of Four Cases and Review of the Literature, Joan M. Duggan, Steven J. Goldstein, Carol E. Chenoweth, Carol A. Kauffman, and Suzanne F. Bradley [2]
- ↑ Cystic Fibrosis Medicine
- ↑ Jakobsen TH, Hansen MA, Jensen PØ, Hansen L, Riber L, et al. (2013) Complete Genome Sequence of the Cystic Fibrosis Pathogen Achromobacter xylosoxidans NH44784-1996 Complies with Important Pathogenic Phenotypes. PLoS ONE 8(7): e68484. doi:10.1371/journal.pone.0068484[http://journals.plos.org/plosone/article? id=10.1371/journal.pone.0068484]
- ↑ Neuwirth C, Freby C, Ogier-Desserrey A, Perez-Martin S, Houzel A, Péchinot A; et al. (2006). "VEB-1 in Achromobacter xylosoxidans from cystic fibrosis patient, France". Emerg Infect Dis. 12 (11): 1737–9. doi:10.3201/eid1211.060143. PMC 3372329. PMID 17283625.
- ↑ Sader HS, Jones RN (2005). "Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli". Int J Antimicrob Agents. 25 (2): 95–109. doi:10.1016/j.ijantimicag.2004.10.002. PMID 15664479.
- ↑ Almuzara M, Limansky A, Ballerini V, Galanternik L, Famiglietti A, Vay C (2010). "In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods". Int J Antimicrob Agents. 35 (1): 68–71. doi:10.1016/j.ijantimicag.2009.08.015. PMID 19889520.
- ↑ Wang M, Ridderberg W, Hansen CR, Høiby N, Jensen-Fangel S, Olesen HV; et al. (2013). "Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis". J Cyst Fibros. 12 (6): 638–43. doi:10.1016/j.jcf.2013.04.013. PMID 23727271.
- ↑ Atalay S, Ece G, Samlioğlu P, Kose S, Maras G, Gonullu M (2012). "Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans". Scand J Infect Dis. 44 (10): 798–801. doi:10.3109/00365548.2012.664780. PMID 22404460.
- ↑ Ciofu O, Hansen CR, Høiby N (2013). "Respiratory bacterial infections in cystic fibrosis". Curr Opin Pulm Med. 19 (3): 251–8. doi:10.1097/MCP.0b013e32835f1afc. PMID 23449384.